Takeda Pharmaceuticals Acquires Inviragen for $250,000,000

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    1613 Prospect Pkwy. Fort Collins, CO 80525
  • Company Description
    Inviragen, Inc. is committed to developing safe, effective vaccines to address this need. Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide.
  • Website
  • Transaction Type
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
  • M&A Terms
    Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.